Clozapine for the treatment of agitated-depressed patients with cognitive impairment: A report of three cases

Nitza Nacasch, Ornah T. Dolberg*, Schmuel Hirschmann, Pinhas Dannon, Leon J. Grunhaus

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Clozapine, an atypical antipsychotic, is mainly approved for the treatment of resistant schizophrenia. However, a substantial body of evidence suggests that it might be useful in other psychiatric indications, such as treatment-resistant depression, Parkinson's disease, and dementia. In this report we present the cases of three patients hospitalized at the psychiatric division of the Sheba Medical Center, diagnosed with major depressive disorder with cognitive impairment, whose presenting symptom was agitation. These patients were nonresponders to various treatment modalities. However, treatment with clozapine brought about a favorable response.

Original languageEnglish
Pages (from-to)132-134
Number of pages3
JournalClinical Neuropharmacology
Volume21
Issue number2
StatePublished - 1998

Keywords

  • Agitation
  • Atypical antipsychotics
  • Clozapine
  • Major depression

Fingerprint

Dive into the research topics of 'Clozapine for the treatment of agitated-depressed patients with cognitive impairment: A report of three cases'. Together they form a unique fingerprint.

Cite this